AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 JUN 2 - (NewsRx.com & NewsRx.net) -- Bovine parainfluenza virus type 3 (PIV-3) vaccine shows promise in studies in rhesus monkeys.
According to recent research published in the Journal of General Virology, "Restricted replication in the respiratory tract of rhesus monkeys is an intrinsic property of bovine parainfluenza virus type 3 (bPIV-3) strains. This host range phenotype of bPIV-3 has been utilized as a marker to evaluate the attenuation of bPIV-3 vaccines for human use. Two safety, immunogenicity and efficacy studies in primates evaluated and compared three human parainfluenza virus type 3 (hPIV-3) vaccine candidates: biologically derived bPIV-3, a plasmid-derived bPIV-3 (r-bPIV-3) and a chimeric bovine/human PIV-3 (b/hPIV-3).
"These studies also examined the feasibility of substituting Vero cells, cultured in the presence or absence of fetal bovine serum, for fetal rhesus lung-2 (FRhL-2) cells as the tissue culture substrate for the production of bPIV-3 vaccine," said Sridhar Pennathur and colleagues at MedImmune Vaccines Inc. "The results demonstrated that: Vero cell-produced bPIV-3 was as attenuated, immunogenic, and efficacious as bPIV-3 vaccine grown in FRhL-2 cells; plasmid-derived bPIV-3 was as attenuated, immunogenic, and efficacious as the biologically derived bPIV-3; and the b/hPIV-3 chimera displayed an intermediate ...
Source: HighBeam Research, Bovine parainfluenza virus type 3 vaccine shows promise in monkeys.